文献速递白血病

新诊断急性髓系白血病中的缓解率、无事件生存期与总生存期:美国食品药品监督管理局的试验水平与患者水平分析

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.
PubMed 文献 · J Clin Oncol · 2021-12-10

该分析纳入8项提交至美国食品药品监督管理局的强化化疗随机对照试验(N=4,482),在试验水平上评估完全缓解(CR)及CR+CRi或CRp的比值比与无事件生存期(EFS)、总生存期(OS)风险比之间的关联,并进行患者水平应答分析。结果显示OS与CR率关联中等,EFS与OS关联强但置信区间宽,CR应答者OS优于CRi或CRp应答者及无应答者。

要点

  • 试验水平上OS风险比与CR比值比关联中等(R2=0.49;95%CI 0.05至0.86)。
  • 统一EFS定义后EFS与OS关联强(R2=0.87;95%CI 0.47至0.98),但置信区间宽。
  • 患者水平CR应答者OS优于CRi或CRp应答者(HR 0.73;95%CI 0.64至0.84)。

核心结论

  • 试验水平上OS与CR率之间存在中等关联,EFS与OS之间观察到强关联但置信区间宽,采用替代EFS定义后结果变为中等。
  • 患者水平分析显示CR应答者OS优于CRi或CRp应答者及无应答者。
  • 新诊断AML中具有EFS获益或CR率显著获益的治疗很可能对OS产生影响。

研究设计与样本

  • 研究类型为试验水平与患者水平分析,数据来自8项提交至美国食品药品监督管理局的强化化疗随机对照试验,共4,482例新诊断急性髓系白血病患者。
  • 试验水平采用加权线性回归模型分析CR及CR+CRi或CRp的比值比与EFS、OS风险比的关联。
  • 患者水平采用应答者分析,汇总所有研究数据比较不同应答者的OS。

主要发现

  • 试验水平分析中,OS风险比与CR比值比的关联为中等(R2=0.49;95%CI 0.05至0.86)。
  • OS风险比与CR+CRi或CRp比值比的关联为中等(R2=0.48;95%CI 0.05至0.99)。
  • 使用原始数据统一各试验EFS定义后,OS与EFS之间观察到强关联(R2=0.87;95%CI 0.47至0.98)。
  • 患者水平应答者分析中,达到CR的患者OS优于CRi或CRp应答者(HR 0.73;95%CI 0.64至0.84)。
  • 达到CR的患者OS优于无应答者(HR 0.33;95%CI 0.31至0.37)。

局限性

  • 置信区间宽。
  • 采用替代EFS定义后关联结果变为中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To explore trial-level and patient-level associations between response (complete remission [CR] and CR + CR with incomplete hematologic [CRi] or platelet [CRp] recovery), event-free survival (EFS), and overall survival (OS) in newly diagnosed acute myeloid leukemia (AML) trials of intensive chemotherapy. METHODS: We identified data from eight randomized, active-controlled trials of intensive chemotherapy submitted to the US Food and Drug Administration for treatment of newly diagnosed AML (N = 4,482). Associations between trial-level odds ratios (ORs) for CR and CR + CRi or CRp, and hazard ratios (HRs) for EFS and OS were analyzed using weighted linear regression models. We performed patient-level responder analyses to compare OS by response using pooled data from all studies. RESULTS: In trial-level analyses, association between HR for OS and OR for CR was moderate (R2 = 0.49; 95% CI, 0.05 to 0.86), as was the association with OR for CR + CRi or CRp (R2 = 0.48; 95% CI, 0.05 to 0.99). For OS versus EFS, a strong association was observed (R2 = 0.87; 95% CI, 0.47 to 0.98) when EFS definitions were harmonized across trials using raw data. In the patient-level responder analyses, patients who achieved CR had better OS compared with CRi or CRp responders (0.73; 95% CI, 0.64 to 0.84) and nonresponders (HR, 0.33; 95% CI, 0.31 to 0.37). CONCLUSION: On a trial level, there is a moderate association between OS and CR rate. A strong association between EFS and OS was observed. However, CIs were wide, and results became moderate using alternative definitions for EFS. Patient-level analyses showed CR responders have better OS compared with CRi or CRp responders and nonresponders. A therapy in newly diagnosed AML with benefit in EFS or substantial benefit in CR rate would be likely to have an OS effect.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Norsworthy KJ, Gao X, Ko CW, et al. Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. J Clin Oncol. 2021. PMID: 34890212. doi:10.1200/JCO.21.01548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。